A phase II trial of an oral methionine aminopeptidase II (MetAP2) inhibitor for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who relapsed after intravesical therapies: Preliminary results

Category Primary study
JournalEuropean Urology, Supplements
Year 2016
This article has no abstract
Epistemonikos ID: 0d995b135b1eec953a07902608cb24815ed3d876
First added on: Feb 07, 2025